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Abstract
Background: Recurrent non-random genomic alterations are the hallmarks of cancer and the characterization
of these imbalances is critical to our understanding of tumorigenesis and cancer progression.
Results: We performed array-comparative genomic hybridization (A-CGH) on cDNA microarrays containing
42,000 elements in neuroblastoma (NB). We found that only two chromosomes (2p and 12q) had gene
amplifications and all were in the MYCN amplified samples. There were 6 independent non-contiguous amplicons
(10.4–69.4 Mb) on chromosome 2, and the largest contiguous region was 1.7 Mb bounded by NAG and an EST
(clone: 757451); the smallest region was 27 Kb including an EST (clone: 241343), NCYM, and MYCN. Using a
probabilistic approach to identify single copy number changes, we systemically investigated the genomic
alterations occurring in Stage 1 and Stage 4 NBs with and without MYCN amplification (stage 1-, 4-, and 4+). We
have not found genomic alterations universally present in all (100%) three subgroups of NBs. However we
identified both common and unique patterns of genomic imbalance in NB including gain of 7q32, 17q21, 17q23-
24 and loss of 3p21 were common to all three categories. Finally we confirm that the most frequent specific
changes in Stage 4+ tumors were the loss of 1p36 with gain of 2p24-25 and they had fewer genomic alterations
compared to either stage 1 or 4-, indicating that for this subgroup of poor risk NB requires a smaller number of
genomic changes are required to develop the malignant phenotype.
Conclusions: cDNA A-CGH analysis is an efficient method for the detection and characterization of amplicons.
Furthermore we were able to detect single copy number changes using our probabilistic approach and identified
genomic alterations specific to stage and MYCN amplification.
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Background
Neuroblastoma (NB) is one of the most common pediat-
ric solid tumors, and accounts for 7–10% of all childhood
cancers. The prognosis of patients with NB varies accord-
ing to the stage, age and MYCN amplification status. Stage
1 disease is essentially curable, whereas patients with stage
4 disease, in particular those with MYCN amplification,
remain largely incurable despite advances in cancer thera-
peutics [1]. Genomic alterations in NB have been investi-
gated by cytogenetic, and molecular methods including
spectral karyotyping and metaphase comparative
genomic hybridization (M-CGH) [2-6]. Based on these
studies several genomic alterations have been reported to
correlate with prognosis including amplification of the
MYCN oncogene (found in 30% of NB) [1,7], gains of
17q (>50%) and loss of 1p36 (30–35%) [1,8,9]. Other
recurrent changes including losses of 3p, 4p, 9p, 11q, and
14q, as well as frequent gain of chromosome 7 have also
been suggested to have relevance to the development and
progression of these tumors [9].
Recently array-based CGH (A-CGH) on BAC and cDNA
microarrays has been used to investigate the genomic
alterations with high resolution [10-14]. cDNA A-CGH
has been successfully utilized to detect amplification and
to investigate the direct effects of genomic changes over
gene expression level by using the same microarray for
both A-CGH and gene expression analysis [14-16]. In this
study, we applied A-CGH, on cDNA microarrays contain-
ing 42,000 elements, to systematically identify common
aberrant genomic alterations in NB of various stages. We
have applied a probabilistic approach to detect single-
copy losses and gains of chromosomal regions. Our study
has three principal aims: 1) Detection and high resolution
mapping of amplicons in NB. 2) Detection of low copy
number genomic alterations using a probabilistic
approach. 3) Establishing a map of genomic imbalances
in NB profiling samples with good (stage 1) and poor
(stage 4 with or without MYCN amplification) prognosis.
Results
Amplicon Mapping by A-CGH
Totally around 24,000 qualified array cDNA clones were
applied for data analysis in 12 NB cell lines and 32 NB pri-
mary tumor samples (see Table 1 for sample informa-
tion). Fig. 1 shows the number of clones as well as the
average spacing for each chromosome. We first deter-
mined the sensitivity of A-CGH to detect the copy number
of highly amplified genes. We here chose MYCN since it is
the most commonly amplified gene in NB and correlates
with the biological behavior of these tumors. Fig. 2A
shows the linear regression plot of the MYCN amplifica-
tion results from A-CGH and Quantitative-PCR (Q-PCR).
We found that the slope of the fitting line was 0.35, and
therefore an observed ratio of 2 by A-CGH corresponds to
Q-PCR ratio of ~6. In order to identify the amplified
regions, we initially selected genes with A-CGH ratio ≥2
for at least two contiguous clones in genome sequence
order. Only two chromosomes (2p and 12q) showed
amplifications by this criterion exclusively in the MYCN
amplified samples. Focusing on 2p (Fig. 2B), we found 6
independent non-contiguous amplicons (10.4–69.4 Mb).
For the MYCN amplicon, the largest contiguous region
was 1.7 Mb and bounded by NAG and an EST (clone:
757451) in three tumor samples, whilst the smallest
region was 27 Kb including an EST (clone: 241343),
NCYM, and MYCN. We identified 9 previously reported
co-amplified genes (HPCAL1, ODC1, NSE1, NAG, DDX1,
NCYM, POMC, DNMT3A, ALK, MEIS1, TEM8) [16,20-
27], and detected the novel amplification of several
known genes (NCOA1, ADCY3, PPP1CB, CGI-127, LBH,
CAPN13,  GalNac-T10,  EHD3,  XDH,  SRD5A2,  CGI-27,
AMP18) and ESTs. Three of the cell lines (CHP134, IMR-
5 and IMR-32) contained two amplicons in 2p13-15. The
first (66.6–67.6 Mb) included previously reported ampli-
fied gene MEIS1, and the size of the second amplicon was
0.3 Mb (69.1–69.4 Mb), which was bounded by
LOC200504 and TEM8. In addition to chromosome 2p,
we identified another amplicon on 12q14-q15 in a single
tumor (NB21); bounded by PRO2268  (68.9 Mb) and
RAB3IP  (69.9 Mb) containing one previously reported
amplified gene (MDM2) [28] as well as several novel
amplifications (CPM, CPSF6, LYZ, GAS41, SNT-1, CCT2,
VMD2L3, and RAB3IP) (Fig. 2C). We verified the amplifi-
cation of NSE1, NAG, DDX1, MYCN and TEM8 by Q-PCR
(data not shown). Simultaneous gene expression profiling
by using the same cDNA arrays for all samples showed
that 47% of the amplified genes correlate with gene
expression (using a correlation coefficient cutoff 0.5; data
not shown).
Detection of low-level DNA copy number alterations
To test the sensitivity of A-CGH to detect single copy
number changes, we performed A-CGH with DNA from
cell lines containing different numbers of X chromosomes
(1–5 copies) [12] and compared them to a sample with 2
copies of X chromosomes. The observed mean fluores-
cence ratio of all clones across X chromosome was calcu-
lated (Fig. 3A). For single copy deletions we observed an
A-CGH ratio 0.9 (expected 0.5). The regression slope was
0.3, similar to that for the MYCN above (Fig 2A). The
underestimation of the expected ratio by A-CGH demon-
strated that it is difficult to detect single-copy changes
using pre-set threshold-based approaches.
In order to increase the sensitivity for detecting low copy
number changes, we applied a probabilistic approach uti-
lizing t-statistics and the local genomic sequence mapping
information of each of the cDNA clones on our arrays. To
validate our method, we re-analyzed the A-CGH dataBMC Genomics 2004, 5:70 http://www.biomedcentral.com/1471-2164/5/70
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generated from the cell lines containing 1–5 copies of the
X chromosome as described above, and we were able to
detect a single copy loss and gain of X chromosome where
the expected ratio was 0.5 and 1.5 respectively (Fig. 3B).
In addition, we used the reported results from the litera-
ture as an independent validation. The cell line SK-N-AS is
deleted within 1p36.2-p36.3, which has been investigated
by FISH and southern blot analysis [29,30]. The proximal
SK-N-AS deletion breakpoint was mapped to between
NPPA and PLOD, while the distal breakpoint is proximal
of CDC2L1. The deletion detected by our method is bor-
dered by KIAA0495 and CTNNBIP1, which is within the
Table 1: Summary of Neuroblastoma Information
Sample No Sample Label Age (yr.mo) Sex Diagnosis MYCN Source
C1 CHP-134B 1.1 M 4 + NCI
C2 GI-LI-N 1.11 M 4 + ICLC
C3 IMR-32 1.1 M 4 + ATCC
C 4 I M R - 5 N DN DN D +I C L C
C5 LAN-1 2 M 4 + ICLC
C6 LAN-5 0.4 M ND + NCI
C7 SK-N-BE(2) 2.2 M 4 + ATCC
C8 SK-N-DZ 2 F ND + ATCC
C9 SMS-KCNR 1.2 M 4 + NCI
C10 SH-SY5Y 4 F 4 - ATCC
C11 SK-N-AS 8 F 4 - ATCC
C12 SK-N-FI 11 M ND - ATCC
C13 SK-N-SH 4 F 4 - ATCC
T1 NB19 12.9 F 1 - DZNSG
T2 NB20 1.3 M 1 - DZNSG
T3 NB229 0.3 M 1 - CHTN
T4 NB248 0.6 M 1 - CHW
T5 NB29 0.3 M 1 - DZNSG
T6 NB33 1.5 F 1 - DZNSG
T7 NB34 1.2 M 1 - DZNSG
T8 NB43 1.1 F 1 - DZNSG
T9 NB44 1.6 M 1 - DZNSG
T10 NB5 0.3 M 1 - DZNSG
T11 NB7 1.3 F 1 - DZNSG
T12 NB9 1.1 M 1 - DZNSG
T13 NB16 3.11 F 4 - DZNSG
T14 NB205 3.11 F 4 - CHTN
T15 NB217 2 M 4 - CHTN
T16 NB24 0.7 M 4 - DZNSG
T17 NB246 3.7 M 4 - CHW
T18 NB247 1.5 M 4 - CHW
T19 NB26 1 M 4 - DZNSG
T20 NB30 0.11 F 4 - DZNSG
T21 NB31 1.4 F 4 - DZNSG
T22 NB32 1.2 M 4 - DZNSG
T23 NB35 2.7 F 4 - DZNSG
T24 NB8 4.7 M 4 - DZNSG
T25 NB14 0.11 M 4 + DZNSG
T26 NB21 5.3 M 4 + DZNSG
T27 NB249 0.8 M 4 + CHW
T28 NB251 0.9 F 4 + CHW
T29 NB252 0.10 F 4 + CHW
T30 NB266 2 F 4 + CHW
T31 NB27 10.6 M 4 + DZNSG
T32 NB28 1.8 F 4 + DZNSG
Abbreviations used are ND: not determined ATCC: American Type Culture Collection, CHTN: Cooperative Human Tissue Network CHW: The 
Children's Hospital at Westmead, Australia, DZNSG: German Cancer Research Center, Heidelberg, ICLC: Interlab Cell Line Collection, NCI: 
National Cancer Institute, NIH. 1Naming convention "C" denotes cell lines, "T" tumors, such that C1 is cell line number 1.BMC Genomics 2004, 5:70 http://www.biomedcentral.com/1471-2164/5/70
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region reported. They are in a very good accordance. In
addition, we also compared the 17q gain results for four
NB cell lines (CHP134, IMR-5, SMS-KCNR, and SK-N-AS)
with the results in literature by FISH and Q-PCR [31]. Our
results confirmed the gains in 17q for all 4 cell lines and
the loss in 17p in SK-N-AS detected by FISH.
We next analyzed the A-CGH data using this method to
detect genome-wide alterations of DNA copy number in
our NB samples. Using this t-statistics, we identified DNA
copy number alterations that involved the majority of the
chromosomes in both primary tumors and cell lines (Fig.
4). We confirmed previously reported genomic changes,
including gains of whole chromosome 1, 2, 6, 7, 8, 12, 13,
17, 18 and 22, and losses of 3, 4, 9, 11, and 14; partial
gains of 1q, 2p, 11p, 12q and 17q; partial losses of 1p, 3p,
4p, 9p, 11q and 14q [9,32]. The most common changes
were losses on chromosome 1p, 4 and 11q; gains on 2p,
7, and 17q.
Stage specific genomic alterations
In order to identify the recurrent regions of genomic alter-
ations that are specific to stage and MYCN amplification
status, we partitioned the tumors into three subgroups
(stage 1, stage 4 MYCN not amplified (4-) and amplified
(4+)), and analyzed the frequency of genomic changes at
each SW-locus (as defined in Methods) for each subgroup.
Since cell lines may contain tissue culture related genomic
alterations, we only used primary NB tumor samples for
this analysis. The frequency of alterations for a given SW-
locus was estimated using the average probability (P)
value as described in the Methods. Fig. 5 shows the
graphic depiction of the P associated with each SW-locus
for all possible pair-wise comparisons among the three
subgroups for gains or losses: Stage 1 vs. 4-, 4+ vs. 4- and
1 vs. 4+. As expected, since the majority of the loci show
no change, they were plotted to values of co-ordinates
around (0.5, 0.5) (shown in black). Regions altered in
both classes with similar frequency are plotted close to the
y = x diagonal, whilst off-diagonal points represented
regions primarily altered in one or the other of the classes
(termed differential imbalance). Loci that plot around
(0,0) reflect loci altered in both groups (termed common
regions). The colored points were selected by using our
criterion for "common" and "specific" SW-locus (see
Methods). In summary, we found alterations that were
common to all three subgroups, which included gain of
7q32, 17q21, 17q23-24 and loss of 3p21. We also found
genomic imbalances that were specific for each of the sub-
groups and common regions of gain for stage 1 and 4-
tumors. Of note there were no shared alterations of 4+
with 1 or 4- besides the regions common to all. A detailed
description and map positions for all these recurrent
regions are provided in the Table 2, and a graphic repre-
sentation of these imbalances is shown in Fig. 5, where we
will discuss in detail in the discussion section.
Discussion
Amplicons in Neuroblastoma
In our study we found that unlike breast cancers [14] NBs
do not have a wide variety of different amplicons or
amplified genes. We identified 6 independent amplicons
on 2p and one on 12q and precisely defined boundaries
for all amplicons. Several genes related to angiogenesis
and oncogenesis were in these novel amplified regions
including  TEM8  (tumor-specific endothelial marker),
mapped to 2p13.1, which has been shown to have ele-
vated expression during tumor angiogenesis [33]. Indeed
this gene was recently reported to be amplified in the cell
line IMR-32 in accord with our data [27]. The gene is
expressed in human endothelium and has been impli-
cated in colorectal cancer. Our present study showed
TEM8 was amplified and over-expressed (data not shown)
in several neuroblastoma cell lines. The significance of
amplification of TEM8 in neuroblastoma cell lines but not
endothelial cells raises an intriguing possibility that these
tumor cells themselves contribute to the angiogenic proc-
ess and requires further investigation. We also identified
amplification of GAS41  (glioma amplified sequence)
mapped to 12q14-q15 in one tumor sample. GAS41, a
transcription factor ubiquitously expressed with the high-
est expression in human brain, was previously shown fre-
quently amplified in human gliomas [34]. ALK
(anaplastic lymphoma kinase) receptor, an oncogene and
reported highly expressed in neuroblastoma [26], was
identified to be amplified in two of our tumor samples. In
Distribution of cDNA clones in our microarray Figure 1
Distribution of cDNA clones in our microarray. Total 
23975 unique UniGene clusters remained from the initial 
42591 clones after quality filtering. Number of clones in each 
chromosome was represented in gray bar on the left side. 
Average spacing (chromosome size/number of clones in the 
chromosome) was represented in black dot on the right side.
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Amplifications in MYCN amplified samples Figure 2
Amplifications in MYCN amplified samples. A. Regression analysis of MYCN ratio (sample vs. normal) obtained from A-
CGH and real-time Q-PCR in all of neuroblastoma samples including 13 cell lines and 32 primary tumors. The slope of the 
regression line is 0.35 indicating that an observed A-CGH ratio of 2 is equivalent to a Q-PCR ratio of 5.7. B. Independent 
amplicons in chromosome 2p. All amplified genes are listed under each amplicon in genome order. Map position, genome 
sequence position (Mb) and samples containing the specific amplicon are listed for each amplicon. The percentage of the MYCN 
amplified samples harboring these amplicons are shown in brackets following the gene name for all clones present in our 
microarray (gray), the remainder of the clones are predicted genes found in the NCBI database http://www.ncbi.nlm.nih.gov/
genome/guide/human/ that are mapped between the boundaries of the amplicon. Amplicons were selected based on the crite-
ria of A-CGH ratio ≥2 for at least two contiguous clones in genome sequence order. In cases where a single clone has a ratio 
<2 but the ratio of its adjacent clones is greater than 2, that single clone was still considered as a part of amplicon. *: previously 
reported amplification. C. Amplicon in chromosome 12q in tumor NB21.
Slope: 0.35
0
20
40
60
80
0 50 100 150 200
Q-PCR Ratio (MYCN)
A-CGH
Ratio
(MYCN)
2pter 2qter
Amp1:
2p25
Amp6:
2p13
Amp5:
2p13-15
Amp2:
2p24-25
Amp4:
2p23
Amp3:
2p23-24
SMS-KCNR MYCN-amplified
samples (16)
NB249 NB249
NB251
CHP134,
IMR32,IMR5
CHP134,
IMR32,IMR5
10.44-10.84 69.13-69.43 Mb 66.60-67.60 28.93-32.22 24.61-25.52 14.77-17.04
LOC200504 (6%)
AMP18 (19%)
TEM8* (19%)
MEIS1* (19%)
LOC351179
Clone:1849449 (19%)
Clone:280592 (19%)
LOC344448
LOC130802
Clone:1751749 (19%)
LOC344449
LOC344450 (19%)
ETAA16* (19%)
LOC285044
Clone:290525 (6%)
Clone:1895144 (6%)
CGI-27 (6%)
LOC84661 (6%)
PPP1CB (6%)
FLJ20628 (6%)
KIAA0007
Clone:49554 (6%)
LOC165186
LOC285131
FLJ21069 (13%)
ALK* (12%)
LOC351137 (13%)
LOC351138
Clone:1837447 (13%)
CGI-127 (13%)
LOC164964
LBH (13%)
LOC285042
LOC351139
LOC285043 (13%)
LOC351140
LOC253558
Clone:814041 (6%)
Clone:297439 (6%)
LOC151124
CAPN13 (6%)
LOC344107 (6%)
GalNac-T10 (6%)
Clone:1467034 (6%)
EHD3 (6%)
LOC351141
XDH (6%)
SRD5A2 (6%)
LOC130450
LOC344108
LOC339736
LOC344302 (6%)
NCOA1 (6%)
MGC11266 (6%)
ADCY3 (6%)
LOC51277 (6%)
KIAA0953 (6%)
Clone:47264 (6%)
POMC* (6%)
LOC344303
Clone:1539905 (6%)
Clone:1700238 (6%)
DNMT3A* (6%)
NSE1* (31%)
Clone:346612 (25%)
LOC351289
LOC351290
NAG* (56%)
PRO2958
DDX1* (81%)
LOC344549
LOC344550
LOC130678
LOC351291
Clone:241343 (94%)
NCYM* (100%)
MYCN* (100%)
LOC344551
LOC344552
LOC344553
LOC348740
LOC351078
LOC351079 (38%)
LOC351080
DKFZP566A1524 (25%)
LOC351081 (19%)
Clone:757451 (19%)
HPCAL1 * (6%)
ODC1 * (6%)
LOC130063
LOC348739
LOC344354
FLJ14075 (6%)
A.
B. C.
Amp:
12q14-15
(NB21: 68.90-69.93 Mb)
PRO2268
MDM2*
MGC5370
CPM
LOC341339
LOC349810
CPSF6
Clone:1897997
Clone:1650934
LYZ
GAS41
LOC283394
LOC338766
LOC349811
SNT-1
Clone:1896673
CCT2
LOC283395
VMD2L3
MGC13168
Clone:126371
LOC341340
RAB3IP
12p13
12p24+1
12p12
12p22
12q14
12q11
12q15
12p11+2
12q13
12q12
12p24+3
12p24+2
12p23
12q21
12p11+1BMC Genomics 2004, 5:70 http://www.biomedcentral.com/1471-2164/5/70
Page 6 of 13
(page number not for citation purposes)
addition to these genes, most of those newly identified
amplified genes have not been implicated previously in
neuroblastoma tumorigenesis and progression; therefore
a further characterization of these genes might provide the
biological insights to neuroblastoma biology. Interest-
ingly, all amplicons occurred in MYCN amplified sam-
ples, and we have not found a single amplicon in MYCN
single copy samples.
Additionally, using our search criterion (A-CGH ratio >2
corresponding to copy number >6 see above) we found
no evidence of amplifications in other chromosomal
regions. This was in conflict with a study by Satito-Ohara
et al. who found evidence of high level gains 9 NB cell
lines and amplification as evidenced by a homogeneous
staining region (HSR) in one line [35]. This difference
could be explained by potential artifacts that arise in cell
lines in tissue culture or be as a result of under detection
by our study because of the relatively small number of
tumor samples in our study, and would require confirma-
tion in a larger sample set.
Detection of low level of genomic changes
In this study, we have applied a t-statistics-based method
to explore genomic alterations in cancer from data
generated by A-CGH on a cDNA microarray platform. Our
method efficiently dealt with the low sensitivity of cDNA
microarrays to detect low copy changes. The microarrays
we utilized contain 42,000 clones, containing around
24,000 unique UniGene clusters with an average coverage
Sensitivity of A-CGH to detect the low-level copy number alteration Figure 3
Sensitivity of A-CGH to detect the low-level copy number alteration. A. Measurement of X-chromosomal copy 
number. A-CGH was performed to analyze the copy number of genes in the X-chromosome. Female DNA (XX) was used as 
the reference DNA. Male DNA (XY), female DNA (XX), and DNA samples containing different number of X-chromosome 
(XXX, XXXX, XXXXX) were used as test DNA, with an expected ratio of test/reference of 0.5, 1.0, 1.5, 2.0, and 2.5 respec-
tively for X-chromosome. Mean fluorescence ratios (±SEM) of autosomal DNAs (blue diamonds) and X-chromosomal DNAs 
(red circles) from each experiment are shown. The slope of the regression line is 0.3. B. Visualization of p-values derived from 
the topological statistics as described in the Methods along the X-chromosome from samples containing different X-chromo-
somal copy numbers. Each column represents a different experiment; and each row represents the p value for the alteration at 
a given SW-locus (a sliding window of 40 adjacent clones, details in Methods), ordered by genome map position from Xpter to 
Xqter. Red represents gain and green loss. The intensity of the color shows the level of significance according to the p-value 
shown in the color scale.
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Genome-wide analysis of DNA copy number alteration by A-CGH Figure 4
Genome-wide analysis of DNA copy number alteration by A-CGH. Samples were grouped based on sample type, 
MYCN amplification status and tumor stage. Each column represents a different sample; and each row represents a p-value of a 
given SW-locus using a sliding window of 40 adjacent clones, ordered in genome order across the whole genome. Black trian-
gles on the right side of image represent centromere positions. Cell-: cell line without MYCN amplification; Cell+: cell line with 
MYCN amplification; Stage 4-: tumor in stage 4 without MYCN amplification; Stage 4+: tumor in stage 4 with MYCN amplifica-
tion. On the right is shown an enlarged view of the region around the MYCN gene (2p24) for the amplified NB samples.
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Genomic alterations specific to stage and MYCN status Figure 5
Genomic alterations specific to stage and MYCN status. Shown is the graphic depiction of the average p-values (P) of 
genomic alteration of each SW-locus (using a sliding window of 20 adjacent clones) within each tumor subgroup. All possible 
pair-wise comparisons among the three subgroups for gains or losses (stage 1 vs 4-, 4+ vs 4- and 1 vs. 4+) are shown. The fre-
quency of alteration is estimated by P such that P = 0.15 is equivalent to a frequency of 70% and the lower the P the higher the 
frequency (details in Methods). Different colors were used to represent different clusters. Magenta: loci common to all groups; 
cyan: common to 1 and 4-; blue: 1 specific; green: 4- specific; red: 4+ specific, and black: all remaining loci. Colored dots were 
enlarged for easier visualization.
Gain (1 vs 4-)
Gain (4+ vs 4-)
Gain (1 vs 4+)
Loss (1 vs 4-)
Loss (4+ vs 4-)
Loss (1 vs 4+)
0.2
0.8
0.6
0.4
0.0
0.0 0.2 0.4 0.6 0.8
P( g a i n|1 )
P
(gain
|
4-)
0.2
0.8
0.6
0.4
0.0
0.0 0.2 0.4 0.6 0.8
P (gain | 4+)
P
(gain
|
4-)
0.2
0.8
0.6
0.4
0.0
0.0 0.2 0.4 0.6 0.8
P (gain | 1)
P
(gain
|
4+)
0.2
0.8
0.6
0.4
0.0
0.0 0.2 0.4 0.6 0.8
P (loss | 1)
P
(loss
|
4-)
0.2
0.8
0.6
0.4
0.0
0.0 0.2 0.4 0.6 0.8
P (loss | 4+)
P
(loss
|
4-)
0.2
0.8
0.6
0.4
0.0
0.0 0.2 0.4 0.6 0.8
P (loss | 1)
P
(loss
|
4+)
Specific to Stage 4+
Specific to Stage 1 Shared by Stage 1 and 4-
Common to all three subgroups Specific to Stage 4-BMC Genomics 2004, 5:70 http://www.biomedcentral.com/1471-2164/5/70
Page 9 of 13
(page number not for citation purposes)
of one cluster every 125 Kb. Underestimation of DNA
copy number ratios by cDNA A-CGH data made it diffi-
cult to detect low level of gains and losses using ratio
threshold based approaches, which was addressed in our
study and previous reports [14-16]. The algorithm we
have implemented included an efficient noise reduction
strategy by combining ratios within a sliding window of
clones as has been previously described [13,14]. However
the incorporation of t-statistics demonstrated several
advantages over the sole reliance of moving average for
detecting genomic changes. It provides confidence levels
for detecting genomic changes at each DNA location (SW-
locus) in terms of p-values. This has theoretical advan-
tages over the original raw ratio, because it incorporates
an estimate of possible statistical errors in the analysis by
giving a p-value attached to each genomic change within
a SW-locus. By this method we were able to detect 1.5 fold
changes of gene copy number as shown in our X-chromo-
some validation experiment.
However, all these advantages are traded for a loss of res-
olution: genomic imbalances much smaller than the win-
dow-size cannot be detected and the boundaries of
instable regions are blurred. Therefore we should choose
the smallest window that has the desired level of statistical
significance. The effective resolution can be obtained by
analyzing the correlation of overlapping sliding windows.
The integrated autocorrelation time is an estimator of the
minimal distance for windows to be effectively uncorre-
lated [36] even when they overlap. For the sliding window
t-test in our algorithm this distance can be calculated to be
half the window size w, thus the number (N) of total
unique Unigene clusters is reduced to 2N/w for the effec-
tively independent measurements of the DNA copy
number. Our results indicate that a window size 20 is
needed in order to detect the lowest possible DNA change
(one copy change) with reasonable statistical significance.
According to the discussion above, this window size
reduces the approximately 24,000 quality filtered unique
Unigene clusters to 2 * 24,000/20 = 2400 independent
estimates. This resolution is comparable to typical BAC
Table 2: Recurrent regions related to MYCN status and stage
Imbalance Chr. Cytoband Start (Mb) End (Mb) Clone No.
Common to 1, 
4-, & 4+
gain 7 7q32 133.19 137.05 26
gain 17 17q21 42.13 53.53 157
gain 17 17q23 55.41 61.8 99
gain 17 17q24 65.59 73.44 70
loss 3 3p21 45.72 46.77 13
Shared by 1 & 4- gain 7 7p14 32.41 32.83 11
gain 7 7q11 69.89 72.34 28
gain 7 7q36 148.74 152.97 39
gain 17 17q12 35.45 36.41 15
gain 17 17q21 39.56 40.03 16
Specific to 1 gain 2 2p22 32.23 33.33 12
gain 17 17p13 2.12 2.59 11
gain 17 17p13 5.67 7.17 22
gain 17 17p13 8.23 9.42 17
loss 8 8p12 38.32 39.84 12
loss 8 8q22-23 109.54 116.64 13
loss 11 11q12 60.87 63.09 29
loss 14 14q12 28.94 31.32 11
loss 14 14q23 58.04 58.76 12
loss 19 19q13 43.4 44.05 13
Specific to 4- gain 7 7p15 24.26 25.89 12
gain 7 7q34 139.53 141.16 22
loss 11 11q21 96.25 96.83 11
loss 11 11q22 108.12 110.64 11
loss 11 11q23 114.31 120.39 51
loss 11 11q24 125.28 126.76 20
loss 11 11q25 131.98 134.08 19
Specific to 4+ gain 2 2p24-25 10.97 20.08 38
loss 1 1p36 6.16 13.42 78
loss 1 1p36 15.22 16.13 20BMC Genomics 2004, 5:70 http://www.biomedcentral.com/1471-2164/5/70
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arrays. For the stronger signals, less noise reduction is
required. To detect 2-copy number DNA changes, only a
small window size 5 is needed, therefore the resolution
will be 4 fold higher. Although cDNA A-CGH is known
not as sensitive as BAC A-CGH for the detection of low
level of DNA copy number changes, currently we are able
to obtain the comparable detection by using the probabi-
listic approach. In addition, with cDNA array it is possible
to identify genomic amplification at the gene level and
investigate the direct effect of gene copy number change
over gene expression level in parallel, which will be
addressed in future studies.
Conclusions
In this study we explored the genomic alterations in NB
from the data generated by A-CGH on a cDNA microarray
platform. We have not found genomic alterations
universally present in all (100%) three subgroups of NBs,
although such a region would be interesting since it may
harbor specific genes that are uniquely responsible for NB
tumorigenesis. We therefore focused on commonly
altered regions where >70% of tumors showed changes in
a given region, for our three different subgroups (Fig. 5
and Table 2). We found only a few of imbalances occur-
ring in all three subgroups, of which gain of 17q21-24 and
loss of 3p21 have been previously described in NB biol-
ogy [8,37]. Apart from these regions stage 4+ tumors did
not have any other regions that commonly change with
the other two stages, whereas stages 1 and 4- had several
common alterations. Stage 4- tumors demonstrated sev-
eral unique changes of which losses in 11q has been pre-
viously described in MYCN single copy NB [38] and acts
as a possible marker of unfavorable phenotype independ-
ent of MYCN  amplification [39]. Remarkably stage 4+
disease appears to have very few genomic alterations
when compared with Stage 1 and 4- implying that MYCN
amplification is sufficient to drive these tumors to an
aggressive phenotype, and although other genomic
changes occur, including loss of 1p36 as shown by us and
others [40], it does not require extensive changes. This is
in agreement with the murine MYCN transgenic model of
NB where the MYCN transgene itself is enough for tumor
development, but these tumors develop additional
genomic changes characteristic of NB [41].
Based on these results we found that cDNA A-CGH analy-
sis is an efficient method for the detection and
characterization of amplicons. We confirmed the previ-
ously reported amplified genes and also identified novel
amplifications in neuroblastoma. Furthermore our prob-
abilistic approach allows the detection of single copy
number changes from cDNA A-CGH and can be applied
to other CGH platforms including BAC or oligonucle-
otides based arrays.
Methods
Tumors, cell lines, and genomic DNA
Thirty-two snap frozen neuroblastoma specimens were
obtained from 12 patients with stage 1, and 20 patients
with stage 4 of which 12 were MYCN-amplified and 8
were MYCN single-copy tumors. The original histological
diagnoses were made at tertiary hospitals with extensive
experience in diagnosis and management of neuroblast-
oma. Additionally, 12 neuroblastoma cell lines including
8 MYCN-amplified and 4 MYCN single copy samples were
used in the study. Details of individual sample are sum-
marized in Table 1. The conditions for cell cultures were
done as described previously [17]. High molecular weight
genomic DNA was extracted from interphase of a Trizol
preparation for RNA extraction according to the manufac-
turer's instructions (Invitrogen, Gaithersburg, MD).
Genomic DNA was treated with RNase A and protease
(Qiagen, Valencia, CA), and purified by phenol/chloro-
form extraction followed by ethanol precipitation. We
obtained normal genomic DNA samples (male, female or
1:1 mixture of male and female) from Promega, and
genomic DNA samples containing the different numbers
of X chromosomes (XXX, XXXX, and XXXXX) from the
NIGMS http://locus.umdnj.edu/nigms/.
Microarray experiments
Preparation of glass cDNA microarrays was performed
according to a previously published protocol [18]. Image
analysis was performed using DeArray software [19]. The
cDNA library containing 42,000 clones was obtained
from Research Genetics (Huntsville, AL) and clones were
printed on two microscope glass slides as a set. Approxi-
mately 50% of the cDNAs on the microarrays were either
known genes or similar to known genes in other organ-
isms, whereas the remainders were anonymous ESTs. For
A-CGH experiments on cDNA microarrays, 20 µg of
genomic DNA from neuroblastoma tumor or cell line
samples were sonicated and purified with QIAquick PCR
purification column (Qiagen, Valencia, CA). Three micro-
grams of sonicated DNA were labeled with aminoallyl-
dUTP (Sigma) in a 25-µl reaction, including random hex-
amer (0.24 µg/µl, Roche), dATP, dCTP and dGTP (125 µM
each), dTTP (25 µM), aminoallyl-dUTP (100 µM) and
high concentration of Klenow fragment (2.5 U/µl, NEB).
The labeling reaction was purified with QIAquick PCR
purification column. Cy3 and Cy5 dyes were coupled to
the reference DNA (1:1 mixture of normal male and
female DNA) and sample DNA respectively. Cy3- and
Cy5-labeled probes were then combined along with
human Cot-1 DNA (50 µg, Invitrogen) and yeast tRNA
(100 µg, Invitrogen). The mixture was concentrated and
re-suspended in 32 µl of hybridization buffer (50% for-
mamide, 10% dextran sulfate, 4 × SSC, and 2% SDS). The
hybridization mix was first heated at 75°C for 10 min,
then at 37°C for an hour, and finally loaded to the pre-BMC Genomics 2004, 5:70 http://www.biomedcentral.com/1471-2164/5/70
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hybridized array. The hybridization was performed at
37°C overnight. The washing procedure was performed as
described previously [17].
Real time quantitative PCR
Real time PCR was carried out using SYBR Green PCR core
reagents according to the manufacturer's instructions
(Applied Biosystems, Foster City, CA). Each DNA sample
was analyzed in triplicate using the ABI PRISM 7000
Sequence Detector. For quantitative PCR, 10 ng of
genomic DNA was used for SYBR green PCR assay. Serial
dilutions of neuroblastoma cell line CHP134 DNA were
used as templates for a standard curve, and the normal
genomic DNA was used as a calibrator. The normalization
was performed as described using BCMA and SDC4 as ref-
erence genes [20].
Data analysis
Fluorescence ratios were normalized for each microarray
by setting the average log ratio for each subarray elements
equal to zero (commonly referred to as "pin-normaliza-
tion"). The data was quality-filtered by removing those
clones with quality lower than 0.5 in more than 20% of
all the samples [19]. For the clones that passed this filter,
if the quality for a specific sample is lower than 0.5, then
its fluorescence ratio is replaced by the average ratio value
of all other samples with the good quality. The clones
were finally assigned to UniGene Cluster (Build 154 Sep-
tember 2002). For the UniGene clusters represented by
multiple clones, mean fluorescence ratios of those clones
are used. After these processes we had 23975 unique Uni-
Gene clusters remaining from the initial 42591 clones.
Map positions for the cluster were assigned by Blat
searches against the "Golden Path" genome assembly
(http://genome.ucsc.edu/; June, 2002 Freeze). Through-
out this publication, all genomic coordinates are given
with the respect to this assembly. Finally the clusters were
sorted according to their starting position of sequence on
each individual chromosome.
Detection of single copy changes
To identify the alterations of copy number along the
genome, we compared the distribution of the ratios in a
sliding window of 20 clones in genomic order with a "null
distribution" using a t-test. The p-value for genomic
change (Pgc) obtained in this way is assigned to the center
of the sliding window (referred to as the "SW-locus"
throughout this manuscript). The t-test is valid in this
instance because the observed distribution of Pgc for the
loci in random order matches the expected theoretical dis-
tribution. The null-distribution used in t-test represents
the unaltered part of genome. To identify the cDNA clones
for the null-distribution, we start with the whole genome.
The SW-loci corresponding to portions of the DNA that
are amplified or deleted with a p-value smaller than 0.05
are removed recursively from the null dataset, until the
null dataset is stable and there is no more amplified or
deleted SW-locus in the null data set. Finally, the confi-
dence of identified genomic alterations is visualized in a
pseudo-color map in which color intensity represents the
log of p-values (red for gain and green for loss).
Estimation of frequency of genomic changes among the 
samples
The probabilistic approach above provides P-values for
the presence of genomic alteration in a given sample. In
order to estimate the frequency of a genomic alteration we
can set a threshold ratio and identify how many samples
have a ratio value outside this threshold in the same
genomic region. The disadvantage of this method is that
different ratio thresholds will give different frequencies.
We therefore applied another approach to avoid the use of
ratio thresholds. To determine the frequency of loss or
gain that correlate with the stage or MYCN amplification
status, we first calculated the mean of the Pgc or P, for each
group. This value is proportional to the frequency fwith
change = Nwith change/Ntotal of their occurrence, where Nwith
change is the number of samples in a subgroup with a given
genomic imbalance and Ntotal is the overall number of
samples in that subgroup. This is valid as follows. For all
loci in which there are no genomic imbalances the
observed Pgc will follow the flat theoretical distribution
with a mean (expectation value) <P> = 0.5. Therefore, for
those cases where we are sure of a genomic imbalance Pgc
is close to 0 (for example p < 0.01), whereas for the sam-
ples in which there are no changes Pgc = 0.5. According to
the formula: P = ((Nno change × 0.5) + (Nwith change × 0))/Nto-
tal = (1 - fwith change) × 0.5, the lower the P the higher the fre-
quency of a genomic change in that SW-locus. Thus the P
can be used to determine the frequency of a given change
e.g. P = 0.15 corresponds to a frequency of ~70% of the
samples with that given change.
Determination of recurrent regions
We first define a SW-locus with P < 0.15 in a specific sub-
group as altered. This threshold corresponds to roughly a
fraction of >70% of all tumor samples harboring that
alteration in each subgroup. We define an altered SW-
locus as common in all tumors, if the SW-locus passes the
threshold for each of the three subgroups. A SW-locus is
called differential in one subgroup with respect to another
subgroup, if the frequency of genomic change is at least 3
times higher in one subgroup as compared to another. A
SW-locus is defined as specific if the locus in one sub-
group is differential with respect to each of the other sub-
groups; a SW-locus is defined as shared in two groups, if
in both groups it is differential with respect to the third
subgroup.BMC Genomics 2004, 5:70 http://www.biomedcentral.com/1471-2164/5/70
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